rs143370729
Variant summary
Our verdict is Uncertain significance. Variant got 5 ACMG points: 5P and 0B. PP3_StrongPP5
The NM_001605.3(AARS1):āc.2251A>Gā(p.Arg751Gly) variant causes a missense change. The variant allele was found at a frequency of 0.000135 in 1,614,142 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_001605.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 5 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000526 AC: 8AN: 152158Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000477 AC: 12AN: 251408Hom.: 0 AF XY: 0.0000442 AC XY: 6AN XY: 135894
GnomAD4 exome AF: 0.000144 AC: 210AN: 1461866Hom.: 0 Cov.: 31 AF XY: 0.000136 AC XY: 99AN XY: 727230
GnomAD4 genome AF: 0.0000525 AC: 8AN: 152276Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74450
ClinVar
Submissions by phenotype
not provided Pathogenic:1Uncertain:1
BS1, PS3_Supporting, PP3, PM1 -
In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 33317386, 26670257, 25817015, 27159321, 31775912, 33294374, 34446925, 32376792, 34490615, 29653220) -
Developmental and epileptic encephalopathy, 29 Pathogenic:1
- -
Charcot-Marie-Tooth disease type 2 Pathogenic:1
This sequence change replaces arginine, which is basic and polar, with glycine, which is neutral and non-polar, at codon 751 of the AARS protein (p.Arg751Gly). This variant is present in population databases (rs143370729, gnomAD 0.009%). This missense change has been observed in individuals with autosomal recessive epileptic encephalopathy (PMID: 25817015, 33294374). It has also been observed to segregate with disease in related individuals. This variant has been reported in individual(s) with autosomal dominant Charcot-Marie-Tooth disease (PMID: 29653220); however, the role of the variant in this condition is currently unclear. ClinVar contains an entry for this variant (Variation ID: 190103). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt AARS protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects AARS function (PMID: 25817015). For these reasons, this variant has been classified as Pathogenic. -
AARS-related disorder Pathogenic:1
This variant has been previously reported in heterozygous, compound heterozygous or homozygous state in patients with AARS-related disorders (PMID: 25817015, 33294374, 29653220). It is present in the heterozygous state in the gnomAD population database at a frequency of 0.005% (13/282822) and thus is presumed to be rare. This variant affects a highly conserved amino acid and is predicted by multiple in silico tools to have a deleterious effect on protein function. Experimental studies have shown that this variant reduces the normal function of the AARS protein (PMID: 25817015). Based on the available evidence, the c.2251A>G (p.Arg751Gly) variant is classified as Likely Pathogenic. -
AARS1-related disorder Pathogenic:1
The AARS1 c.2251A>G variant is predicted to result in the amino acid substitution p.Arg751Gly. This variant has been reported in the compound heterozygous and homozygous state in individuals with early infantile epileptic encephalopathy (Simons et al. 2015. PubMed ID: 25817015). This variant has been reported in in the compound heterozygous in an individual with acute liver failure (Marten et al. 2020. PubMed ID: 33294374). This variant has also been reported in an individual with autosomal dominant Charcot-Marie-Tooth disease (Table S5, Vaeth et al. 2018. PubMed ID: 29653220). In addition, functional studies indicate this variant impairs the aminoacylation activity of the AARS protein (Simons et al. 2015. PubMed ID: 25817015; Marten et al. 2020. PubMed ID: 33294374). This variant is reported in 0.0093% of alleles in individuals of European (Non-Finnish) descent in gnomAD and has conflicting interpretations regarding its pathogenicity in ClinVar, ranging from uncertain to pathogenic (https://www.ncbi.nlm.nih.gov/clinvar/variation/190103/). This variant is interpreted as likely pathogenic. -
Charcot-Marie-Tooth disease Uncertain:1
- -
Inborn genetic diseases Uncertain:1
The p.R751G variant (also known as c.2251A>G), located in coding exon 15 of the AARS gene, results from an A to G substitution at nucleotide position 2251. The arginine at codon 751 is replaced by glycine, an amino acid with dissimilar properties. This alteration was detected in an individual among a cohort of Charcot-Marie-Tooth disease patients (Vaeth S et al. Eur J Med Genet, 2019 Jan;62:1-8). Furthermore, functional studies showed reduced aminoacylation activity in vitro (Simons C et al. Am J Hum Genet, 2015 Apr;96:675-81). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. However, based on data from gnomAD, the frequency for this variant is above the maximum credible frequency for a disease-causing variant in this gene based on internally established thresholds (Karczewski et al. Nature. 2020 May;581(7809):434-443; Whiffin et al. Genet Med. 2017 10;19:1151-1158). Since supporting evidence is conflicting at this time, the clinical significance of this alteration remains unclear. -
Charcot-Marie-Tooth disease axonal type 2N Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at